153 related articles for article (PubMed ID: 32420002)
1. Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program.
Borrelli EP; Lee EY; Caffrey AR
Ment Health Clin; 2020 May; 10(3):70-75. PubMed ID: 32420002
[TBL] [Abstract][Full Text] [Related]
2. Assessing prescribing practices of clozapine before and after the implementation of an updated risk evaluation and mitigation strategy.
Curry B; Palmer E; Mounce C; Smith G; Shah V
Ment Health Clin; 2018 Mar; 8(2):63-67. PubMed ID: 29955547
[TBL] [Abstract][Full Text] [Related]
3. Clozapine-associated neutropenia and agranulocytosis in Argentina (2007-2012).
Balda MV; Garay OU; Papale RM; Bignone I; Bologna VG; Brandolini A; Prokopez CR; Balasini JI; Baldessarini RJ; Daray FM
Int Clin Psychopharmacol; 2015 Mar; 30(2):109-14. PubMed ID: 25486383
[TBL] [Abstract][Full Text] [Related]
4. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization.
Huynh-Le MP; Shults RC; Connor MJ; Hattangadi-Gluth JA
Clin Genitourin Cancer; 2020 Jun; 18(3):192-200.e2. PubMed ID: 31902714
[TBL] [Abstract][Full Text] [Related]
5. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System.
Borrelli EP; Lee EY; Descoteaux AM; Kogut SJ; Caffrey AR
Epilepsia; 2018 Dec; 59(12):2318-2324. PubMed ID: 30395352
[TBL] [Abstract][Full Text] [Related]
6. Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM.
Toyserkani GA; Huynh L; Morrato EH
Front Public Health; 2020; 8():43. PubMed ID: 32158741
[No Abstract] [Full Text] [Related]
7. Clozapine-induced agranulocytosis and leukopenia: Incidence, associated factors, and rate of hematologic adverse-effects monitoring in psychiatric out-patient services in Thailand.
Tunsirimas N; Pariwatcharakul P; Choovanichvong S; Ratta-Apha W
Asian J Psychiatr; 2019 Mar; 41():13-16. PubMed ID: 30856469
[TBL] [Abstract][Full Text] [Related]
8. Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014-2018).
Huynh L; Toyserkani GA; Morrato EH
BMC Health Serv Res; 2021 Aug; 21(1):779. PubMed ID: 34362367
[TBL] [Abstract][Full Text] [Related]
9. Anatomy of Risk Evaluation and Mitigation Strategies (REMS).
Loeser KK; McKoy JM; Schumock GT
Cancer Treat Res; 2019; 171():93-105. PubMed ID: 30552659
[TBL] [Abstract][Full Text] [Related]
10. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future Direction.
Wu J; Juhaeri J
Clin Ther; 2016 Dec; 38(12):2526-2532. PubMed ID: 27914632
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of clozapine-induced granulocytopenia with lithium (two observations)].
Papetti F; Darcourt G; Giordana JY; Spreux A; Thauby S; Feral F; Pringuey D
Encephale; 2004; 30(6):578-82. PubMed ID: 15738861
[TBL] [Abstract][Full Text] [Related]
12. Making Rash Decisions in Epilepsy: Evaluating Hypersensitivity Reactions to Anti-seizure Medications.
Bermeo-Ovalle A
Epilepsy Curr; 2019; 19(2):96-98. PubMed ID: 30955419
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review.
Heyward J; Olson L; Sharfstein JM; Stuart EA; Lurie P; Alexander GC
JAMA Intern Med; 2020 Feb; 180(2):301-309. PubMed ID: 31886822
[TBL] [Abstract][Full Text] [Related]
14. The Modernization of Clozapine: A Recapitulation of the Past in the United States and the View Forward.
Leung JG; de Leon J; Frye MA; Singh B; Cotes RO; McElroy SL
J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):565-580. PubMed ID: 36170148
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.
Rollman JE; Heyward J; Olson L; Lurie P; Sharfstein J; Alexander GC
JAMA; 2019 Feb; 321(7):676-685. PubMed ID: 30778596
[TBL] [Abstract][Full Text] [Related]
16. Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: framework and experience.
Dharmani C; Wang E; Salas M; McCabe C; Diggs A; Choi Y; Jiang J; Keedy VL
Future Oncol; 2022 Apr; 18(13):1595-1607. PubMed ID: 35105158
[TBL] [Abstract][Full Text] [Related]
17. Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis-stimulating agents and transfusion in patients with chemotherapy-induced anaemia.
Hollingsworth K; Romney MC; Crawford A; McAna J
J Clin Pharm Ther; 2015 Jun; 40(3):299-303. PubMed ID: 25893427
[TBL] [Abstract][Full Text] [Related]
18. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
19. APhA 2011 REMS white paper: Summary of the REMS stakeholder meeting on improving program design and implementation.
American Pharmacists Association ; Bough M
J Am Pharm Assoc (2003); 2011; 51(3):340-58. PubMed ID: 21555285
[TBL] [Abstract][Full Text] [Related]
20. What is the quality of drug safety information for patients: An analysis of REMS educational materials.
Chan HW; Russell AM; Smith MY
Pharmacoepidemiol Drug Saf; 2018 Sep; 27(9):969-978. PubMed ID: 30003610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
